Robust T cell Responses Reported Across Diverse HLA backgrounds in Ph 2 AMPLIFY-7P Trial of ELI-002
Robert Connelly, Chief Executive Officer of Elicio, commented, “We are extremely pleased to see that mKRAS-specific T cell responses are induced among patients with a diverse HLA background, suggesting that ELI-002 7P may be applicable to a broad range of PDAC patients potentially addressing a key unmet need and expanding the potential market opportunity. Our observations build on past data to show that the majority of patients express mKRAS-presenting HLAs, likely enabling T cell recognition in most patients. These encouraging findings highlight the potential for ELI-002 7P to benefit a broader spectrum of PDAC patients, which may extend the reach of immunotherapy to more individuals and address a critical unmet need.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib